NCT06441318

A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

A Phase 1, Randomized, Partially Double-Blind, Placebo- and Positive-Controlled, Parallel Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 128 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effect of povorcitinib on the QT/QTc Interval in healthy participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	Povorcitinib	Povorcitinib will be administered at protocol defined dose.
DRUG	Placebo	Placebo will be administered at protocol defined dose.
DRUG	Moxifloxacin	Moxifloxacin will be administered at protocol defined dose.

Timeline

• Start date: 2024-07-12
• Primary completion: 2024-09-10
• Completion: 2024-09-10
• First posted: 2024-06-04
• Last updated: 2024-09-25

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study